SEARCH:   Advanced

Blood, 15 August 2008, Vol. 112, No. 4, pp. 1308-1316. Prepublished online as a Blood First Edition Paper on June 5, 2008; DOI 10.1182/blood-2008-04-149831. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-04-149831v1 112/4/1308    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chang, D. H. Articles by Dhodapkar, M. V. Search for Related Content PubMed PubMed Citation Articles by Chang, D. H. Articles by Dhodapkar, M. V. Related Collections Immunobiology Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer David H. Chang1, Haiteng Deng2, Phillip Matthews1, Joseph Krasovsky1, Govind Ragupathi3, Radek Spisek1, Amitabha Mazumder4, David H. Vesole4, Sundar Jagannath4, and Madhav V. Dhodapkar1,57 1 Laboratory of Tumor Immunology and Immunotherapy and 2 Proteomics Resource Center, Rockefeller University, New York, NY; 3 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; 4 St Vincent's Cancer Center, New York, NY; 5 Chris Browne Center for Immunologic Diseases, Rockefeller University, New York, NY; 6 Section of Hematology, Yale University, and 7 Program in Hematologic Malignancies, Yale Cancer Center, New Haven, CT CD1d-restricted T cells have been implicated in the pathogenesis of several chronic inflammatory states. However, the nature of the specific ligands recognized by these cells in vivo in patients with inflammatory or malignant diseases remains unknown. We took a biochemical approach to directly isolate and characterize the nature of CD1d-binding ligands from the plasma of myeloma patients. Characterization of these ligands revealed several lysophosphatidylcholine (LPC) species. Human LPC-CD1d dimer binding cells are T-cell receptorβ+ T cells but predominantly V24–Vβ11–. Cytokine secretion by LPC-specific T cells is skewed toward IL-13 secretion, and the frequencies of these cells are increased in myeloma patients relative to healthy donors. These data identify a distinct population of human CD1d-restricted T cells specific for inflammation-associated lysolipids and suggest a novel mechanism for inflammation mediated immune regulation in human cancer. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. V. Dhodapkar and N. Neparidze NKT cells in p53 deficiency Blood, June 18, 2009; 113(25): 6268 - 6269. [Abstract] [Full Text] [PDF] W. Yuan, S.-J. Kang, J. E. Evans, and P. Cresswell Natural Lipid Ligands Associated with Human CD1d Targeted to Different Subcellular Compartments J. Immunol., April 15, 2009; 182(8): 4784 - 4791. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020